Lineage Cell Therapeutics
Tuesday, June 04, 2024
Company Presentation
![Regenerative Medicine](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 3
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its proprietary cell-based therapy platform and in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, differentiated, and allogeneic human cell therapies. Lineage’s clinical and preclinical programs include five product candidates: (i) OpRegen, a retinal pigment epithelial cell therapy being developed for the treatment of geographic atrophy under a worldwide collaboration with Roche and Genentech; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a for the treatment of spinal cord injury; (iii) VAC2, a dendritic cell therapy in Phase 1 for the treatment of non-small cell lung cancer; (iv) ANP1, an auditory neuronal progenitor cell therapy for hearing loss treatment; and (v) PNC1, a photoreceptor neural cell therapy for the treatment of vision loss.
![Lineage Cell Therapeutics](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1776437-1-JPG.png)
Company Website:
https://lineagecell.com/
Lead Product in Development:
OpRegen
Number Of Unlicensed Products (For Which You Are Seeking Partners):
4
Exchange
NYSE
Ticker
LCTX
Company HQ City
Carlsbad
Company HQ State
CA
Company HQ Country
United States
CEO/Top Company Official
Brian Culley
Development Phase of Primary Product
Phase II
Primary Speaker